NASDAQ:TVTX Stock Quote
18.32
-1.36 (-6.89%)
Travere Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly those associated with kidney disorders
The company’s mission is to address significant unmet medical needs and improve the quality of life for individuals affected by these conditions. By leveraging advanced research and development capabilities, Travere aims to deliver targeted treatments that can help manage or potentially reshape the course of rare kidney diseases, ultimately striving to empower patients and their families through effective therapeutic options.

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.
Via Stocktwits · February 11, 2025

The company is nearing a highly anticipated approval for a kidney disease drug.
Via Investor's Business Daily · February 11, 2025

Via Benzinga · February 11, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via Investor's Business Daily · January 9, 2025

While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.
Via MarketBeat · November 11, 2024

Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker.
Via Benzinga · October 23, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 17, 2024

Via Benzinga · October 16, 2024

Via Benzinga · October 10, 2024

The company could soon ask for approval of its only drug, Filspari, in a second disease.
Via Investor's Business Daily · October 9, 2024

Via Benzinga · September 27, 2024

Via Benzinga · September 27, 2024

Via Benzinga · September 26, 2024

Via Benzinga · September 9, 2024

Via Benzinga · September 6, 2024

The company previously had an accelerated approval for its IgA nephropathy treatment.
Via Investor's Business Daily · September 6, 2024

Via Benzinga · September 6, 2024
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus royalties.
Via Talk Markets · July 27, 2024